ClinicalTrials.gg
CompletedNCT07408115Updated Feb 12, 2026

Herbal Dietary Supplementation on Vasomotor Symptoms in Menopausal Women

An interventional study of JDS-HF3.0 in Hot Flashes, Hot Flash and Hot Flushes, Menopause, Postmenopause, sponsored by Bonafide Health. Completed at 1 site in United States. Open to female participants aged 40 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-02-12.

Sponsored by Bonafide Health (part of Otsuka Holdings Co., Ltd.) · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 6 months after the study started (first participant enrolled May 2024, registered Nov 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
112
Allocation
Not applicable
Ages
40 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 193 studies in Hot Flashes with a site in United States — 26 open to participants now, 27 under way, 2 of them phase 3. Hot Flashes · United States.

Enrollment
68th of 180
112 · median 84
Started
2024
with 3 others
No phase
74 of 193
16 open now
Registered
182nd of 193
by date

Among the 193 studies in Hot Flashes with a site in United States, this one is the 68th largest by enrollment of the 180 interventional ones that give a count, is one of 4 that started in 2024, is one of 74 with no phase, and was the 182nd registered.

Hot Flashes

339 studies on the registry are indexed under Hot Flashes; 56 are open to participants now.

Browse Hot Flashes studies →

Open to participants now

26 of the 193 studies in Hot Flashes with a site in United States are open now. Recruiting first, the newest first:

21 more — sign in →

All 26 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 37 Hot Flashes studies recruiting now, 13 (35%) set no upper age limit and 22 (59%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 40 Years to 70 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 193 studies in Hot Flashes with a site in United States, or all of them as a file.
02

Study summary

The goal of this study is to evaluate the efficacy of a neurokinin 1,3 antagonist on improving vasomotor symptoms (VMS) and overall menopause symptoms in women between the ages of 40-70. The primary research question is whether taking the study product daily for 4 weeks with an optional 8 week extension, significantly reduces the severity and frequency of menopause-related symptoms.

Read the detailed description

About 200 women across the U.S. will take part in this open label trial. All participants will take the study product and will be instructed to consume two tablets each morning for 4 weeks. Participants will be offered the option to enroll in an 8 week extension after the 4 week supplementation period. During this extension, participants will be asked to continue supplementing with the study product at the same dosing regimen. If a participant opts out of the extension, the total time the participant will be in the study is 5 weeks, including baseline data collection. If a participant opts into the 8 week extension, the total time the participant will be in the study is 12 weeks.

This is a remotely-delivered trial with no in-person assessments. Participants will take part in four virtual check-ins, including a pre-screening visit, a screening visit, a baseline visit, and a initial end of study visit. If a participant opts into the 8 week extension, there will be two additional virtual visits that are each conducted 4 weeks apart, including a end-of-extension visit. Throughout the study, participants will be asked to complete daily diaries and weekly and monthly questionnaires to report on their symptoms and how they are feeling. Questions included in these assessments ask about hot flashes, night sweats, physical comfort, and overall well-being. The study is led by a research team based in Harrison, NY, USA.

03

Conditions studied

  • Hot Flashes
  • Hot Flash
  • Hot Flushes, Menopause, Postmenopause
  • Hot Flushes and/or Sweats
  • Hot Flushes
  • Night Sweats
  • Vasomotor Symptoms
  • Vasomotor Symptoms (VMS)
  • Vasomotor Symptoms Associated With Menopause

Browse trials for

Keywords

  • Postmenopausal
  • Post menopause
  • Vasomotor Symptoms
  • Night sweats
  • Hot Flashes
  • Hot Flushes
  • Non-hormonal Treatment
  • Supplement
04

Who can participate

Ages eligible
40 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy women who are 40 to 70 years of age (inclusive).
  2. Have a (BMI) between 18.5 to 34.9 kg/m2 (inclusive).
  3. Have self-reported menopausal symptoms for the past 6 months.
  4. Have self-reported ≥5 moderate to severe hot flashes per day, on average for 7 days.
  5. In good general health (no active or uncontrolled diseases or conditions) and able to consume the study product.
  6. Agree to refrain from treatments listed in the defined timeframe.
  7. Willing and able to agree to the requirements and restrictions of this study, be willing to give voluntary consent, be able to understand and read the questionnaires, and carry out all study-related procedures.

Exclusion criteria

Exclusion Criteria:

  1. Individuals who are lactating, pregnant, or planning to become pregnant during the study.
  2. Use of any treatment for menopausal symptoms or other concomitant treatments listed.
  3. Have a known sensitivity, intolerability, or allergy to any of the study products or their .
  4. Received a vaccine for COVID-19 in the two weeks prior to screening or during the study period, current COVID-19 infections, or currently have the post COVID-19 condition as defined by World Health Organization (WHO) (i.e., individuals with a history of probable or confirmed SARS-CoV-2 infection, usually three months from the onset of COVID-19 with symptoms that last for at least two months and cannot be explained by an alternative diagnosis).
  5. Have a positive medical history of heart disease, renal disease, hepatic impairment, or active systemic infection (i.e., Lyme disease, TB, ).
  6. History of cancer (except localized skin cancer without ) within two years prior to screening.
  7. History of any disease or disorder which, in the opinion of the investigator, may either put the potential subject at risk because of participation in the study or influence the results or the potential subject's ability to participate in the study.
  8. History or presence of gastrointestinal, hepatic, or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs (i.e., Crohn's disease, short bowel, acute or chronic pancreatitis, gastric bypass procedures, or pancreatic insufficiency).
  9. Active vaginal infections/abnormalities (e.g., active urinary tract infection (UTI), genital hemorrhage of unknown origin, pelvic inflammatory disease (PID)). Note: screened participants with infections would be eligible to participate two weeks after completing their treatment ().
  10. Participant has an abnormality or obstruction of the gastrointestinal tract precluding swallowing (e.g., dysphagia) and digestion (e.g., known intestinal malabsorption, celiac disease, inflammatory bowel disease, chronic pancreatitis, steatorrhea).
  11. Major surgery in three months prior to screening or planned major surgery during the study.
  12. History of alcohol or substance abuse in the last 5 years.
  13. Use of any vaginal medications, cooling devices, cooling mattresses, cooling sprays, or patches purposed for hot flash control (i.e., V-qool patch, estrogen cream, etc.) one week before and during study. Note: Screened participants that are willing to undergo a washout of at least two weeks or possibly longer and abstain from using above products during the duration of their participation will be enrolled.
  14. Previous participation in a Bonafide Health run clinical trial on Hot Flashes using Bonafide HF-3.0.
  15. Participation in another clinical or research trial.
  16. Any other active or unstable medical conditions or use of medications/supplements/ therapies that, in the opinion of the investigator, may adversely affect the participant's ability to complete the study or its measures or pose a significant risk to the participant.
  17. Currently incarcerated prisoners.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
112 participants (actual)

Study arms

  • Experimental
    Active: JDS-HF3.0 Active Group

    All participants supplementing with JDS-HF3.0

    Dietary Supplement: JDS-HF3.0

Interventions

  • Dietary supplementJDS-HF3.0

    Active Supplement JDS-HF3.0

06

What researchers measure

Primary outcomes

  1. Change from Baseline on Hot Flash Symptoms assessed by the number and severity of hot flashes and times awakened at night due to night sweats collected via participant diary tracking electronically.

    Study diary will be completed by participants daily from Day -7 to -1 to establish a pre-dose baseline and then from Day 1 to Day 28 ± for the initial study duration. If a participant participates in the optional extension, they will be asked to continue completing the diaries for an additional 56 ± 3 days, for a total of 84 ± 3 days. The information recorded will be the number and severity of hot flashes that occurred, the number of night sweats and severity, any changes in concomitant medication/dietary supplement information, and any changes in health (Day 1 to 84 ± 3). Efficacy outcomes include daily diary results (number and severity of hot flashes and number of times awakened at night due to night sweats)

    Time frame: From enrollment to initial end of study at 8 weeks and/or end of study at optional 12 weeks

  2. Change from Baseline on Hot Flash Symptoms assessed via Hot Flash Related Daily Interference Scale (HFRDIS) scores.

    The HFRDIS measures the impact of hot flashes on overall quality of life and nine specific activities (work, social activities, sleep, mood, leisure activities, concentration, enjoyment of life, sexuality, and relations with others).The rating scale ranges from 0-10, with 0 being does not interfere, and 10 being completely interferes. A higher score indicates a worse outcome.

    Time frame: From enrollment to initial end of study at 8 weeks and/or end of study at optional 12 weeks

  3. Change from Baseline on Hot Flash Symptoms assessed via the Visual Analog Scale Vasomotor Symptoms Questionnaire (VAS).

    The Visual Analog Scale (VAS) has symptoms recorded on a 10-cm line that represents a continuum between the two ends of a scale -"not bothered" on the left end (0cm) of the scale and "extremely bothered" on the right end (10 cm) of the scale. Subjects mark one point on that continuum, and researchers measure the distance from that point to one of the ends of the scale. Response options range from 0-100, with a higher score reflecting the worse outcome.

    Time frame: From enrollment to initial end of study at 8 weeks and/or end of study at optional 12 weeks

  4. Change from Baseline on Overall Menopausal Symptoms assessed via the Greene Climacteric Scale (CGS).

    The GCS was a scale created to be a brief and standardized method to measure climacteric symptoms or complaints. Each of the 21 items is scored between 0-3, with 0 being not at all bothered and 3 being extremely bothered. There are three sub-scales that are measured, which include vasomotor, physical and psychological symptoms. Responses with a higher score reflect a worse outcome.

    Time frame: From enrollment to initial end of study at 8 weeks and/or end of study at optional 12 weeks

  5. Change from Baseline on Overall Menopausal Symptoms assessed via the Menopause Rating Scale (MRS).

    The MRS is a self-administered scale that scores eleven items on a 5-point scale, with 0 being no complaints and 4 being very severe symptoms. Each question is rated on a 5-point scale, with the higher number correlating with the more severe symptoms and worse outcome.

    Time frame: From enrollment to initial end of study at 8 weeks and/or end of study at optional 12 weeks

  6. Change from Baseline on Overall Menopausal Symptoms assessed via the Visual Analog Scale Vasomotor Symptoms Questionnaire (VAS).

    The Visual Analog Scale (VAS) has symptoms recorded on a 10-cm line that represents a continuum between the two ends of a scale -"not bothered" on the left end (0cm) of the scale and "extremely bothered" on the right end (10 cm) of the scale. Subjects mark one point on that continuum, and researchers measure the distance from that point to one of the ends of the scale. Response options range from 0-100, with a higher score reflecting the worse outcome.

    Time frame: From enrollment to initial end of study at 8 weeks and/or end of study at optional 12 weeks

Secondary outcomes

  1. Change from Baseline of Sleep Quality assessed via the Patient-Reported Outcomes Measurement Information System Sleep Disturbance Short Form (PROMIS SD SF).

    The Patient-Reported Outcomes Measurement Information System Sleep Disturbance Short Form (PROMIS SD SF) assesses self-reported perceptions of sleep, including difficulties and concerns with getting to sleep or staying asleep, satisfaction of sleep, and overall sleep quality. This form does not focus on symptoms of specific sleep disorders; it is universal rather than disease-specific. It assesses sleep disturbance over the past seven days

    Time frame: From enrollment to initial end of study at 8 weeks and/or end of study at optional 12 weeks

  2. Change from Baseline of Quality of Life assessed via the menopause-specific quality of life (MENQOL)

    The MENQOL is a quality-of-life questionnaire that is specific to postmenopausal women.There are 29 questions that ask questions pertaining to symptoms or problems that are directly related to menopause. Each question being scored from 0 to 6, 0 being not at all bothered and 6 being extremely bothered, with 6 being the worse outcome.

    Time frame: From enrollment to initial end of study at 8 weeks and/or end of study at optional 12 weeks

  3. Change from Baseline on Joint pain and discomfort assessed via the Joint Questionnaire

    Change from baseline in scores in the Joint Questionnaire. The Joint Questionnaire is a modified version of the validated Musculoskeletal Questionnaire to include more relevant and joint pain/discomfort specific questions. The questionnaire contains eight questions focused on joint and/or muscular pain, discomfort, and or soreness in the past two weeks. Questions include multiple-choice answers based on severity and frequency.

    Time frame: From enrollment to initial end of study at 8 weeks and/or end of study at optional 12 weeks

Other outcomes

  1. Safety and Tolerability assessed via participant electronic diaries

    Safety and adverse events (e.g., GI distress, headaches) will be collected from participant electronic diaries or in the event there is an adverse event that a participant contacts the study team this will be documented directly by the study team. Each virtual visit will also include a safety/adverse event check in with a study team member.

    Time frame: From enrollment to initial end of study at 8 weeks and/or end of study at optional 12 weeks

07

Study locations

1 site
  • Bonafide Health
    Harrison, New York 10528, United States
08

References and documents

Publications

  • Heinemann K, Ruebig A, Potthoff P, Schneider HP, Strelow F, Heinemann LA, Do MT. The Menopause Rating Scale (MRS) scale: a methodological review. Health Qual Life Outcomes. 2004 Sep 2;2:45. doi: 10.1186/1477-7525-2-45. PubMed 15345062 ↗
  • Thurston RC, Bromberger JT, Joffe H, Avis NE, Hess R, Crandall CJ, Chang Y, Green R, Matthews KA. Beyond frequency: who is most bothered by vasomotor symptoms? Menopause. 2008 Sep-Oct;15(5):841-7. doi: 10.1097/gme.0b013e318168f09b. PubMed 18521049 ↗
  • Sussman M, Trocio J, Best C, Mirkin S, Bushmakin AG, Yood R, Friedman M, Menzin J, Louie M. Prevalence of menopausal symptoms among mid-life women: findings from electronic medical records. BMC Womens Health. 2015 Aug 13;15:58. doi: 10.1186/s12905-015-0217-y. PubMed 26271251 ↗
  • Delgado DA, Lambert BS, Boutris N, McCulloch PC, Robbins AB, Moreno MR, Harris JD. Validation of Digital Visual Analog Scale Pain Scoring With a Traditional Paper-based Visual Analog Scale in Adults. J Am Acad Orthop Surg Glob Res Rev. 2018 Mar 23;2(3):e088. doi: 10.5435/JAAOSGlobal-D-17-00088. eCollection 2018 Mar. PubMed 30211382 ↗
  • Hilditch JR, Lewis J, Peter A, van Maris B, Ross A, Franssen E, Guyatt GH, Norton PG, Dunn E. A menopause-specific quality of life questionnaire: development and psychometric properties. Maturitas. 1996 Jul;24(3):161-75. doi: 10.1016/s0378-5122(96)82006-8. PubMed 8844630 ↗
  • Yu L, Buysse DJ, Germain A, Moul DE, Stover A, Dodds NE, Johnston KL, Pilkonis PA. Development of short forms from the PROMIS sleep disturbance and Sleep-Related Impairment item banks. Behav Sleep Med. 2011 Dec 28;10(1):6-24. doi: 10.1080/15402002.2012.636266. PubMed 22250775 ↗
  • Greene JG. Constructing a standard climacteric scale. Maturitas. 1998 May 20;29(1):25-31. doi: 10.1016/s0378-5122(98)00025-5. PubMed 9643514 ↗
  • Carpenter JS. The Hot Flash Related Daily Interference Scale: a tool for assessing the impact of hot flashes on quality of life following breast cancer. J Pain Symptom Manage. 2001 Dec;22(6):979-89. doi: 10.1016/s0885-3924(01)00353-0. PubMed 11738160 ↗
  • Scoglio S, Benedetti S, Canino C, Santagni S, Rattighieri E, Chierchia E, Canestrari F, Genazzani AD. Effect of a 2-month treatment with Klamin, a Klamath algae extract, on the general well-being, antioxidant profile and oxidative status of postmenopausal women. Gynecol Endocrinol. 2009 Apr;25(4):235-40. doi: 10.1080/09513590802632506. PubMed 19408172 ↗
  • https://doi.org/10.1177/20533691231172565
  • Greene JG. Constructing a standard climacteric scale. Maturitas. 2008 Sep-Oct;61(1-2):78-84. doi: 10.1016/j.maturitas.2008.09.011. PubMed 19434881 ↗
  • Bannu SM, Lomada D, Gulla S, Chandrasekhar T, Reddanna P, Reddy MC. Potential Therapeutic Applications of C-Phycocyanin. Curr Drug Metab. 2019;20(12):967-976. doi: 10.2174/1389200220666191127110857. PubMed 31775595 ↗
  • Ataei-Almanghadim K, Farshbaf-Khalili A, Ostadrahimi AR, Shaseb E, Mirghafourvand M. The effect of oral capsule of curcumin and vitamin E on the hot flashes and anxiety in postmenopausal women: A triple blind randomised controlled trial. Complement Ther Med. 2020 Jan;48:102267. doi: 10.1016/j.ctim.2019.102267. Epub 2019 Nov 26. PubMed 31987231 ↗
  • Umland EM, Falconieri L. Treatment options for vasomotor symptoms in menopause: focus on desvenlafaxine. Int J Womens Health. 2012;4:305-19. doi: 10.2147/IJWH.S24614. Epub 2012 Jul 5. PubMed 22870045 ↗
  • Utian WH. Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: a comprehensive review. Health Qual Life Outcomes. 2005 Aug 5;3:47. doi: 10.1186/1477-7525-3-47. PubMed 16083502 ↗
  • Menopause, 2017, U.S. Food and Drug Administration/Center for Drug Evaluation and Research: Washington, DC. Accessed.

Individual participant data

Plan to share: No — Data will be privately owned.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2024 to primary completion in Dec 2024, 6 months.

Of 67 interventional studies with no phase under Hot Flashes, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 34. This study's 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2025
First posted
Feb 12, 2026
StartActual
May 24, 2024
Primary completionActual
Dec 18, 2024
CompletionActual
Dec 18, 2024
Last update
Feb 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07408115
Lead sponsor
Bonafide Health
Responsible party
Trisha VanDusseldorp (Dr. Trisha VanDusseldorp, Principle Investigator, Bonafide Health) — Principal investigator
First posted
Feb 12, 2026
Start date
May 24, 2024
Primary completion
Dec 18, 2024
Completion
Dec 18, 2024
Last update
Feb 12, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion